Archives

Perfusfind S.L.

Abstract Purpose of review  Cardiogenic shock is a condition that is characterized by end-organ hypoperfusion secondary to reduced cardiac output, and is associated with substantial mortality. The mainstay of therapy..

Perfusfind S.L.

Abstract Bronchovenous  (BVF) is a rare complication and can cause arterial gas embolism in vital organs, including the heart and the brain, resulting in a high mortality rate. A 51-year-old man..

Perfusfind S.L.

Abstract Background PEEP selection in severe COVID-19 patients under extracorporeal membrane oxygenation (ECMO) is challenging as no study has assessed the alveolar recruitability in this setting. The aim of the..

Perfusfind S.L.

Abstract Acute brain injury (ABI) occurs frequently in patients receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO). We examined the association between peri-cannulation arterial carbon dioxide tension (PaCO2) and ABI with granular..

Perfusfind S.L.

Abstract Introduction Advanced age is a known risk factor for poor outcomes after veno-arterial extracorporeal membrane oxygenation (V-A ECMO) for cardiac support. The use of ECMO support in patients over..

Perfusfind S.L.

Abstract Background Research evaluating hemostatic agents for the treatment of clinically significant bleeding has been hampered by inconsistency and lack of standardized primary clinical trial outcomes. Clinical trials of hemostatic..

Perfusfind S.L.

Abstract We aimed to evaluate the outcomes of post‑traumatic acute respiratory distress syndrome (ARDS)in young patients with and without Extracorporeal membrane oxygenation (ECMO) support. A retrospective analysis was conducted for..

Perfusfind S.L.

Abstract Background: The benefit of extracorporeal membrane oxygenation (ECMO) for patients with severe acute respiratory distress from coronavirus disease 2019 refractory to medical management and lung-protective mechanical ventilation has not been..

Perfusfind S.L.

Abstract Objective: Extracorporeal membrane oxygenation (ECMO) use in adult patient populations has grown rapidly with wide variation in practices and outcomes. We evaluated the impact on patient outcomes, resource use, and..

Perfusfind S.L.

Abstract Objectives Extracorporeal membrane oxygenation (ECMO) involves complex coagulation management and frequent hemostatic complications. ECMO practice between centers is variable. To compare results between coagulation studies, standardized definitions and clear..

Perfusfind S.L.

Abstract Purpose Venoarterial  (VA ECMO) effectively supports refractory  (rCS), and sustains macro- and . We investigated the respective impact of increasing VA ECMO flow or  dose on microcirculation in stabilized VA ECMO–treated patients with..

Perfusfind S.L.

Abstract Introduction: Patients receiving extracorporeal membrane oxygenation (ECMO) often require renal replacement therapy (RRT). The challenge of inserting a dialysis catheter (DC) could be solved by direct connection of RRT lines..

Perfusfind S.L.

Abstract Background During extracorporeal life support (ECLS), bleeding is one of the most frequent complications, associated with high morbidity and increased mortality, despite continuous improvements in devices and patient care...

Perfusfind S.L.

Abstract This systematic review summarizes the major developments in extracorporeal membrane oxygenation (ECMO) circuitry in pediatrics over the past 20 years and demonstrates the impacts of those developments on clinical..

Perfusfind S.L.

Abstract An editorial published in April 2022 discusses the benefits and pitfalls of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with intra-aortic balloon pumps (IABP) to manage CS. The complete manuscript,..

Perfusfind S.L.

Abstract The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) following acute myocardial infarction with cardiogenic shock (AMI-CS) is increasing, but the ability to predict favorable outcomes with support remains limited...

Perfusfind S.L.

Abstract Although mechanical circulatory support (MCS) has been used to support patients with cardiogenic shock (CS) for many years, recent advances in device technology, together with the lackluster performance of..

Perfusfind S.L.

Abstract Introduction In peripheral percutaneous (VA) extracorporeal membrane oxygenation (ECMO) procedures the femoral arteries perfusion route has inherent disadvantages regarding poor upper body perfusion due to watershed. With the advent..

Perfusfind S.L.

Abstract Introduction Although extracorporeal membrane oxygenation (ECMO) has been associated with improved outcomes in COVID patients with respiratory failure, data regarding the need for blood product utilization in this population..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) support requires skills that can only be found in specialized centers. The number of patients annually supported with ECMO is positively associated with the survival..

Perfusfind S.L.

Abstract The use of extracorporeal membrane oxygenation (ECMO) is growing rapidly in all patient populations, especially adults for both acute lung or heart failure. ECMO is a complex, high risk,..

Perfusfind S.L.

Abstract Introduction Extracorporeal Membrane Oxygenation (ECMO) may be used in the setting of pregnancy or the peripartal period, however its utility has not been well-characterized. This study aims to give..

Perfusfind S.L.

Abstract Introduction: Extracorporeal membrane oxygenation (ECMO) is an important treatment option for organ support in respiratory insufficiency, cardiac failure, or as an advanced tool for cardiopulmonary resuscitation. Reports on pediatric..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) use is increasing worldwide, driven by device simplification and increasing need during the coronavirus disease 2019 (COVID-19) pandemic, while bleeding and thrombotic events remain a..

Perfusfind S.L.

Abstract Anticoagulation during extracorporeal membrane oxygenation (ECMO) for Coronovirus Disease 2019 (COVID-19) can be performed by direct or indirect thrombin inhibitors but differences in outcomes with these agents are uncertain...

Perfusfind S.L.

Abstract Tocilizumab is known to improve outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia. However, little is known about its utility in patients with COVID-19 who require respiratory..

Perfusfind S.L.

Abstract Refractory hypoxemia despite the use of extracorporeal membrane oxygenation (ECMO) for coronavirus disease 2019 (COVID-19)–related acute respiratory distress syndrome remains a challenging problem. A single ECMO circuit may not..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is a life-saving therapy utilized for patients with severe life-threatening cardiorespiratory failure. Patients treated with ECMO are among the most severely ill encountered in critical..

Perfusfind S.L.

Abstract Objectives:  The use of extracorporeal membrane oxygenation (ECMO) in patients with COVID-19 has been supported by major healthcare organizations, yet the role of specific management strategies during ECMO requires..

Perfusfind S.L.

Abstract A retrospective study was performed examining the trend of inflammatory markers, including D-dimers, in 29 COVID-19 patients requiring veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support. We observed that COVID-19..